BlinkLab
- Company typePublic
- Founded2021
- HeadquartersPrinceton, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
BlinkLab firmographics
Firmographics- Name
- BlinkLab
- Legal name
- BlinkLab Limited
- Website
- https://blinklab.org
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BlinkLab industry classification
Industry- Product category
- Digital Health Diagnostics
- NAICS
- Child and Youth Services (62411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Autism Diagnostic & Educational Assessment Services (EDAKAKAA), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where BlinkLab is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
BlinkLab business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- BlinkLab Dx1 (Autism Diagnostic): AI-powered smartphone-based diagnostic aid for autism. Following FDA 510(k) clearance and CE marking, the company plans to commercialize through healthcare systems and specialist centers. Revenue model will likely involve licensing fees to clinical institutions.
- BlinkLab Dx2 (ADHD Diagnostic): Diagnostic adjunct for ADHD using the same platform. The company plans to initiate FDA 510(k) registrational trial for Dx2 following Dx1 approval. Will leverage same commercial infrastructure as Dx1.
- Research Platform Licensing: BlinkLab offers its technology platform to research institutions for remote neurobehavioral testing in clinical studies. The company provides access to its app and online portal, with data retained by BlinkLab as AI training assets.
- International Screening Programs: Nationwide autism screening agreements with governments or foundations (e.g., Morocco's Foundation Mohammed V for Solidarity) where commercial fees are renegotiated upon FDA clearance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One-time | Clinical Study Participant Compensation |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
BlinkLab product offering
Product offeringCore offering
BlinkLab develops and sells an AI-powered smartphone-based neurobehavioral diagnostic platform that uses computer vision and auditory stimuli to objectively measure reflexive responses (eyeblinks, acoustic startle, prepulse inhibition) as biomarkers for autism (Dx1) and ADHD (Dx2). The platform consists of a mobile app (iOS), online research portal, and cloud infrastructure, designed for at-home clinical assessment of children as young as 18 months, with results shared securely with healthcare professionals and researchers.
Product overview
BlinkLab is a digital health company offering a smartphone-based neurobehavioral diagnostic platform for autism and ADHD. The platform consists of a mobile app (iOS), an online research portal, and cloud infrastructure. Two diagnostic modules share this core platform: BlinkLab Dx1 for autism detection (under FDA 510(k) review and CE/MDR approval) and BlinkLab Dx2 for ADHD diagnosis (in development). Both modules use the same smartphone app and portal but employ different digital biomarkers derived from audio-visual neurobehavioral testing. The platform delivers auditory stimuli via headphones while using computer vision to track facial and eyelid responses, providing objective reflex-based measures to support clinicians in assessing neurodevelopmental conditions in children as young as 18 months.
Differentiator
Problem solved
Functional benefit
Brands
- BlinkLab Dx1: AI-powered autism diagnostic aid - a smartphone-based neurological assessment designed to provide rapid, accessible, and accurate autism screening for children as young as 18 months old.
- BlinkLab Dx2
Products and services
- BlinkLab Dx1 AI-powered smartphone-based diagnostic aid for autism that uses computer vision and audio stimuli to measure reflexive eyelid responses (acoustic startle response and prepulse inhibition) as objective biomarkers for autism detection in children as young as 18 months. Currently undergoing FDA 510(k) registrational trial and CE/MDR approval process for licensing to healthcare systems and specialist centers.
- BlinkLab Dx2 ADHD diagnostic adjunct that uses the same smartphone technology, app, and online portal as Dx1 but employs different digital biomarkers generated by a child's interaction with the app to evaluate brain function and detect possible indicators of ADHD. Will leverage the same commercial infrastructure as Dx1 once approved.
- BlinkLab Smartphone Neurobehavioral Testing Platform Core smartphone-based neurobehavioral testing platform consisting of a mobile app (iOS, requiring iPhone X or newer or iPad 9th generation+, iOS 15.0+), online research portal, and cloud infrastructure. Delivers reflexive tests (acoustic startle response, prepulse inhibition, eyeblink conditioning, habituation) via audio stimuli through headphones while computer vision tracks facial/eyelid responses. Test sessions take approximately 12–20 minutes with children watching engaging videos. Licensed to research institutions for large-scale remote neurobehavioral testing in clinical studies.
Quantifiable outcome
- 83.7% sensitivity and 84.7% specificity in pilot study, exceeding FDA required thresholds of >65% for both metrics
- +4 more outcomes
Companies that use BlinkLab
Customer profileNamed customers13 records
Segments5 records
Ideal customer profiles4 records
BlinkLab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature7 records
BlinkLab partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered supporting and core.
- Erasmus MC (Therapy Evaluation)supportingAcademic research agreement expanding into therapy evaluation for neurodevelopmental conditions including autism. Study focuses on APDS (Activated PI3K Delta Syndrome) associated with neurodevelopmental symptoms. Moves BlinkLab beyond diagnostics into therapy monitoring.
- Foundation Mohammed V for Solidarity (Morocco)coreNationwide autism screening agreement to deploy Dx1 smartphone-based screening technology across Morocco's national health system (38 million population). Generates real-world clinical validation data for FDA 510(k) trial. All data retained exclusively by BlinkLab as IP asset.
- IQVIA-MCRAcoreContract Research Organisation (CRO) leading and conducting the FDA 510(k) pivotal validation study to ensure full adherence to study protocols and data quality.
- Drexel UniversitycoreNinth clinical site for pivotal FDA 510(k) trial. Drexel's A.J. Drexel Autism Institute is nationally recognized for population-level autism surveillance, diagnostic access, and evidence-based policy development.
- Rush University Medical CentercoreEighth premier US autism center for FDA 510(k) trial of smartphone-based diagnostic aid. Multidisciplinary autism services integrating expert clinicians, evidence-based assessment, and comprehensive family support.
- Vanderbilt Kennedy CentercoreInterdisciplinary institute at Vanderbilt University dedicated to advancing autism research. Part of Autism Care Network improving standards of care. Joins FDA 510(k) trial network for autism diagnostic.
- Seattle Children's Research InstitutecoreGlobally recognized leader in pediatric research and innovation in children's health. Center for Child Health, Behavior and Development is pioneer in autism research providing critical insights into early diagnosis and intervention.
- Netherlands Autism Register (NAR) / VU AmsterdamcoreFirst study evaluating BlinkLab autism detection app in adults and late-diagnosed autism, with emphasis on women. NAR has 6,800 active participants. Part of SCANNER consortium. IRB-approved study with 200 participants commencing April 2025.
- Columbia UniversitycoreClinical study in patients with spinocerebellar ataxias (SCA) to study effect of aerobic physical exercise on neuroplasticity. Uses BlinkLab eyeblink conditioning test as biomarker for motor learning. Study will recruit up to 62 adults over 18 months.
- Monash University (MAGNET Project)coreCollaboration with landmark MAGNET Project enrolling 1,000 families with children diagnosed with autism, ADHD, or both. Study aims to identify data-driven subtypes using deep phenotyping. BlinkLab paying A$389,398 in fees over 24-month term.
- INTER-PSYcoreClinical trial partnership for autism diagnosis supporting US and EU regulatory approval. Large autism expertise centre in Netherlands for children, adolescents, adults. Part of SCANNER consortium investigating sex differences in autism.
- Mental Care GroupcoreStrategic partnership with fifth largest outpatient mental health care provider in Europe. Pilot study validated technology in clinical setting for ADHD diagnosis. Preliminary study in 184 participants showed children with ADHD have significantly heightened sensory sensitivity. Exclusive partnership in Netherlands for ADHD, depression and anxiety.
- Erasmus University Medical CentercoreClinical study on early diagnosis of frontotemporal dementia (FTD) and Alzheimer's using BlinkLab's smartphone-based remote assessment including eyeblink conditioning (EBC) and prepulse inhibition (PPI). Also includes therapy evaluation partnership for APDS neurodevelopmental conditions.
- Bates CollegesupportingClinical study to assess BlinkLab smartphone test for Functional Neurological Disorder (FND) diagnosis. Study led by Dr. Olivia Kim recruiting up to 500 patients across Maine, New York, New Jersey over 3 years.
- Turning Pointe Autism FoundationcoreClinical study in children with autism using AI-powered diagnostic tools. Study involves up to 200 children (100 diagnosed with autism, 100 without) to finalize AI/ML algorithms for larger FDA registration study.
- Princeton UniversitycoreBlinkLab was founded by Princeton University neuroscientists. The original research and development of the smartphone-based neurobehavioral testing platform occurred at Princeton. The company leverages ongoing collaboration with Princeton researchers including Dr. Sam Wang.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
BlinkLab competitors and assessment
Company assessmentDirect peers
- Cognoa: Cognoa is the closest direct competitor: it has already secured FDA clearance for an AI-powered autism diagnostic (Canvas Dx) using a smartphone-based approach, occupying the exact regulatory and clinical niche BlinkLab is targeting.
- EarliTec Diagnostics: EarliTec has FDA-cleared eye-tracking-based autism diagnostic tools, making it a direct US regulatory and commercial competitor in objective, technology-mediated autism assessment.
- Qbtech: Qbtech provides FDA-cleared objective ADHD testing (QbTest), directly comparable to BlinkLab's planned Dx2 ADHD diagnostic adjunct that uses the same sensorimotor gating biomarker concept.
- Akili Interactive: Akili is a publicly-traded digital therapeutics company with FDA-cleared products in ADHD (EndeavorRx), sharing BlinkLab's digital therapeutic / SaMD regulatory pathway and pediatric neurodevelopmental focus.
Emerging players
- Altoida: Altoida uses smartphone-based digital biomarkers and AI for early detection of cognitive decline and Alzheimer's, sharing BlinkLab's computer-vision-measures-neurometrics technology architecture but focused on neurodegeneration rather than neurodevelopment.
- Linus Health: Linus Health applies smartphone- and tablet-based digital cognitive assessments with AI/ML for early detection of dementia, paralleling BlinkLab's smartphone-first, computer-vision-driven biomarker model in an adjacent neurology category.
- Behavior Imaging Solutions: Behavior Imaging Solutions offers remote autism assessment and telebehavioral health tools, competing in the same remote autism evaluation workflow that BlinkLab's Dx1 is designed to enable.
- Quadrant Biosciences: Quadrant Biosciences develops multi-modality diagnostics (including epigenetic saliva-based tests) for autism and ADHD, serving the same clinical need for objective pediatric neurodevelopmental assessment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BlinkLab social profiles
Digital presenceBlinkLab financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlinkLab leadership team
Management profileNumber of profiles
Profiles10 records
BlinkLab funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlinkLab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlinkLab
What does BlinkLab do?
BlinkLab develops and sells an AI-powered smartphone-based neurobehavioral diagnostic platform that uses computer vision and auditory stimuli to objectively measure reflexive responses (eyeblinks, acoustic startle, prepulse inhibition) as biomarkers for autism (Dx1) and ADHD (Dx2). The platform consists of a mobile app (iOS), online research portal, and cloud infrastructure, designed for at-home clinical assessment of children as young as 18 months, with results shared securely with healthcare professionals and researchers.
Is BlinkLab a public or private company?
BlinkLab is a public company. It is classified as public and is currently operating.
When was BlinkLab founded?
BlinkLab was founded in 2021. It employs 11 to 50 people.
Where is BlinkLab based?
BlinkLab is headquartered in Princeton, United States, in the North America region.
How does BlinkLab make money?
Four revenue lines are on record. BlinkLab Dx1 (Autism Diagnostic) is the primary driver. The others are blinkLab Dx2 (ADHD Diagnostic), research Platform Licensing and international Screening Programs.
Who are BlinkLab's main competitors?
Direct peers on record are Cognoa, EarliTec Diagnostics, Qbtech and Akili Interactive. Emerging players are Altoida, Linus Health, Behavior Imaging Solutions and Quadrant Biosciences.
Does BlinkLab have an API?
No public API is recorded for BlinkLab.
What industry is BlinkLab in?
BlinkLab's product category is Digital Health Diagnostics. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 62411 and its SIC code is 7372.